Radiodermatitis Market trends during the forecast period 2021-2027 will be influenced by the increasing burden of cancer and the rise in radiation therapy for its treatment globally. Cancer is a leading cause of death across the world and accounted for more than 10 million deaths during 2020, according to WHO. Increasing occurrence of radiodermatitis in cancer patients and ongoing research activities for the development of effective solutions for its treatment are propelling the market growth.
Radiodermatitis, also popularly known as radiation dermatitis, is a skin conditions observed in individuals undergoing radiation therapy for treatment of cancer or certain skin disorders. Common symptoms of the condition include redness, itching, peeling, flaking, blister, soreness, and others. Radiation dermatitis can be very painful for cancer patients. A wide range of products and solutions are available for its treatment and newer ones are constantly entering the market.
Based on the route of administration, the topical segment is likely to experience rapid growth in the market up to 2027. Topical solutions are easy to apply and are known to deliver faster results. Manufacturers are focusing on product innovation to meet the increasing market demand as well as latest regulatory standards. In July 2020, for instance, KeraNetics Inc’s KeraStat range of wound dressing ointments had received the U.S. for treatment of radiation dermatitis.
In terms of the regional landscape, the North American market is slated to record lucrative growth over 2021-2027, led by the widespread occurrence of cancer and dominant use of radiotherapy for treatment of various types of cancer. The America Cancer Society estimates that more than 608,570 cancer related deaths will occur in 2021. Ongoing investments in cancer research, government efforts to boost cancer awareness, and the rise in radiation therapy for cancer treatment will positively impact the regional industry dynamics.
3M Company, Smith & Nephew, Acelity (3M Company), Derma Sciences (Integra LifeSciences Holdings Corporation), Molnlycke Health Care (Investor AB), ConvaTec, Stratpharma, LETI Pharma, BMG Pharma and Alliqua BioMedical are a few established names in the market. Investments in research and development and product innovation are top priorities for these companies due to the increasing market progression for radiodermatitis treatment patients. These companies are focusing on developing novel solutions that comply with regulatory requirements and industry standards.
The coronavirus pandemic has affected each and every aspect of the healthcare sector including cancer care. The market has had mild to moderate impact owing to the pandemic. At the onset of the COVID-19 pandemic in 2020, elective medical procedures and treatments, including radiation therapy, were largely put on hold in order to prioritize urgent needs and minimize the spread of infection to cancer patients in healthcare facilities. This had resulted in a significant drop in radiotherapy procedures.
However, cancer care gradually has started returning to normal in many regions with necessary protection, protocols, and precautionary measures. radiation therapy will continue to be one of the most effective and safest treatment options for cancer patients, which will positively stimulate the market outlook through 2027.